Trial Profile
A pharmacokinetics study to demonstrated the bioequivalence of JR-051.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2020
Price :
$35
*
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus First in man; Pharmacokinetics
- 17 Jun 2020 Results presented in a JCR Pharmaceuticals media release.
- 01 May 2020 Results published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders.
- 05 Oct 2017 New trial record